The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy

Fabio Perversi¹, Cinzia Costa^{2

3}, Angelo Labate⁴, Simona Lattanzi⁵, Claudio Liguori^{6

7}, Marta Maschio⁸, Stefano Meletti^{9

10}, Lino Nobili^{11

12}, Francesca Felicia Operto^{13

14}, Andrea Romigi^{15

16}, Emilio Russo¹⁴, Carlo Di Bonaventura¹⁷

Affiliations

¹ Polistudium s.r.l., Milan, Italy.
² Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
³ Neurological Clinic, S. Maria Della Misericordia Hospital, Perugia, Italy.
⁴ Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
⁵ Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
⁶ Department of Systems Medicine, University of Rome 'Tor Vergata", Rome, Italy.
⁷ Epilepsy Center, Neurology Unit, University Hospital "Tor Vergata", Rome, Italy.
⁸ Center for Tumor-Related Epilepsy, UOSD Neuro-Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁹ Neurology Department, University Hospital of Modena, Modena, Italy.
¹⁰ Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy.
¹¹ Child Neuropsychiatry Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
¹² Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Child and Maternal Health (DINOGMI), University of Genova, Genova, Italy.
¹³ Child and Adolescent Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
¹⁴ Department of Science of Health, School of Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
¹⁵ Sleep Medicine Center, Neurological Mediterranean Institute IRCCS Neuromed, Pozzilli, Italy.
¹⁶ Psychology Faculty, International Telematic University Uninettuno, Rome, Italy.
¹⁷ Epilepsy Unit, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

PMID: 37483446
PMCID: PMC10359664
DOI: 10.3389/fneur.2023.1182304

Review

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy

Fabio Perversi et al. Front Neurol. 2023.

. 2023 Jul 6:14:1182304.

doi: 10.3389/fneur.2023.1182304. eCollection 2023.

Authors

Affiliations

¹ Polistudium s.r.l., Milan, Italy.
² Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
³ Neurological Clinic, S. Maria Della Misericordia Hospital, Perugia, Italy.
⁴ Neurophysiopatology and Movement Disorders Clinic, University of Messina, Messina, Italy.
⁵ Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
⁶ Department of Systems Medicine, University of Rome 'Tor Vergata", Rome, Italy.
⁷ Epilepsy Center, Neurology Unit, University Hospital "Tor Vergata", Rome, Italy.
⁸ Center for Tumor-Related Epilepsy, UOSD Neuro-Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁹ Neurology Department, University Hospital of Modena, Modena, Italy.
¹⁰ Department of Biomedical, Metabolic, and Neural Sciences, University of Modena and Reggio-Emilia, Modena, Italy.
¹¹ Child Neuropsychiatry Unit, IRCCS Istituto G. Gaslini, Genova, Italy.
¹² Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Child and Maternal Health (DINOGMI), University of Genova, Genova, Italy.
¹³ Child and Adolescent Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy.
¹⁴ Department of Science of Health, School of Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
¹⁵ Sleep Medicine Center, Neurological Mediterranean Institute IRCCS Neuromed, Pozzilli, Italy.
¹⁶ Psychology Faculty, International Telematic University Uninettuno, Rome, Italy.
¹⁷ Epilepsy Unit, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.

PMID: 37483446
PMCID: PMC10359664
DOI: 10.3389/fneur.2023.1182304

Abstract

Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily compose basic neuronal networks, especially in the cortex. An imbalance of excitatory and inhibitory activities may result in epilepsy or other neurological and psychiatric conditions. Among glutamate receptors, AMPA receptors are the predominant mediator of glutamate-induced excitatory neurotransmission and dictate synaptic efficiency and plasticity by their numbers and/or properties. Therefore, they appear to be a major drug target for modulating several brain functions. Perampanel (PER) is a highly selective, noncompetitive AMPA antagonist approved in several countries worldwide for treating different types of seizures in various epileptic conditions. However, recent data show that PER can potentially address many other conditions within epilepsy and beyond. From this perspective, this review aims to examine the new preclinical and clinical studies-especially those produced from 2017 onwards-on AMPA antagonism and PER in conditions such as mesial temporal lobe epilepsy, idiopathic and genetic generalized epilepsy, brain tumor-related epilepsy, status epilepticus, rare epileptic syndromes, stroke, sleep, epilepsy-related migraine, cognitive impairment, autism, dementia, and other neurodegenerative diseases, as well as provide suggestions on future research agenda aimed at probing the possibility of treating these conditions with PER and/or other AMPA receptor antagonists.

Keywords: AMPA antagonists; AMPA receptors; epilepsy; glutamate; migraine; perampanel; sleep.

PubMed Disclaimer

Conflict of interest statement

CC has received research support, speaker honoraria, and travel expenses from Bial, Eisai Europe Limited, GW Pharma, Lusopharma, PIAM Pharma, and UCB Pharma. CB has received consulting fees or speaker honoraria from UCB Pharma, Eisai, GW Pharmaceuticals, Bial, and Lusopharma. AL has received consulting fees or speaker honoraria from UCB Pharma, Eisai, GW Pharmaceuticals, Bial, and Lusopharma. SL has received speaker or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, and UCB Pharma, and has served on Angelini Pharma, Arvelle Therapeutics, BIAL, EISAI, and GW Pharmaceuticals advisory boards. SM has received speaker or consultancy fees from Eisai, GW Pharmaceuticals, and UCB Pharma and has served on advisory boards for Eisai, UCB and GW Pharmaceuticals. LN has received speaker or consultancy fees from Fidia Pharma, Eisai, and Roche. FO has received speaker or consultancy fees from Eisai, GW Pharmaceuticals, and Angelini Pharma; FP is a collaborator of Polistudium SRL and was compensated for medical writing in accordance with the Good Publication Practice 2022. AR has received consulting fees or speaker honoraria from Angelini Pharma, EISAI, Jazz, and Bioprojet. ER has received speaker fees or funding and has participated in advisory boards for Arvelle Therapeutics, Angelini, Eisai, Kolfarma, JAZZ pharmaceuticals, Pfizer, GW Pharmaceuticals, UCB, and Lundbeck. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother (2017) 18:1751–64. doi: 10.1080/14656566.2017.1392509 - DOI - PubMed
1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. . ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia (2017) 58:512–21. doi: 10.1111/epi.13709 - DOI - PMC - PubMed
1. Bonansco C, Fuenzalida M. Plasticity of hippocampal excitatory-inhibitory balance: missing the synaptic control in the epileptic brain. Neural Plast (2016) 2016:8607038. doi: 10.1155/2016/8607038 - DOI - PMC - PubMed
1. Hanada T. Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors. Biomol Ther (2020) 10:464. doi: 10.3390/biom10030464 - DOI - PMC - PubMed
1. Chen S, Xu D, Fan L, Fang Z, Wang X, Li M. Roles of N-methyl-D-aspartate receptors (NMDARs) in epilepsy. Front Mol Neurosci (2022) 14:797253. doi: 10.3389/fnmol.2021.797253 - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy

Affiliations

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources